DISCLAIMER — Not financial advice. Educational content only, not an offer or solicitation to buy or sell any security. Biotech and small/mid-cap stocks are highly speculative and volatile and can result in a partial or total loss of capital. Do your own research and consult a licensed advisor where appropriate.
Merlintrader Trading Pub
Biotech catalyst news and analysis. FDA PDUFA tracker
Merlintrader Trading Pub
Biotech catalyst news and analysis. FDA PDUFA tracker
?? English Version
? Cue Biopharma (CUE)
Investment Research Report — Platform Play: Immuno-STAT T-Cell Modulators
Update: November 26, 2025
⚠️ GOING CONCERN WARNING
? STRATEGIC PIVOT TO AUTOIMMUNE
NASDAQ: CUE | Price: ~$0.61 | Market Cap: ~$47M | 52-Week Range: $0.45 – $5.12
Table of Contents
1. Executive Summary
Cue Biopharma is a clinical-stage biotech developing Immuno-STAT biologics — injectable drugs that selectively modulate disease-relevant T-cells without broad immunosuppression. The platform has applications in both oncology and autoimmune diseases.
In July 2024, the company announced a strategic pivot to prioritize autoimmune programs (CUE-401) while seeking partners for its oncology assets (CUE-101, CUE-102). This represents a fundamental shift from cancer-focused to autoimmune-focused biotech.
Investment Profile:
- NOT a near-term binary catalyst play like CAPR or typical PDUFA stocks
- Medium-term thesis: CUE-401 IND filing (mid-2026) + potential oncology partnering deals
- Near-term cash events: ImmunoScape $10M payment (Q4 2025)
- High risk: Going concern warning, limited cash runway, early-stage pipeline
2. Pipeline Overview
? CUE-101 (Oncology — Lead Clinical Asset)
Phase 1 Seeking PartnerTarget: HPV16-driven cancers (HNSCC, cervical, anal, oropharyngeal)
Mechanism: IL-2-based Immuno-STAT that activates HPV16-specific T-cells
Status: Mono and combo (+ pembrolizumab) Phase 1 ongoing; mature survival data accumulating
Key Data: 50% ORR in combo, 12-month OS 88%, median OS 32.7 months
? CUE-102 (Oncology)
Phase 1 Seeking PartnerTarget: WT1-expressing solid tumors (ovarian, pancreatic, AML)
Status: Early Phase 1, dose escalation
⭐ CUE-401 (Autoimmune — LEAD PROGRAM)
Preclinical / IND-EnablingTarget: Treg “master switch” — selective Treg activation without broad immunosuppression
Indication: Atopic dermatitis (first indication); potential in multiple autoimmune diseases
Status: IND-enabling studies; Pre-IND feedback positive from FDA
Timeline: IND filing expected mid-2026
? CUE-501 (Partnered with Boehringer Ingelheim)
PartneredPartner: Boehringer Ingelheim
Economics: $12M upfront + up to $345M milestones + royalties
Status: Boehringer responsible for development
3. Recent Strategic Deals
? ImmunoScape Collaboration (November 2025)
| Type | Strategic Collaboration & License |
| Focus | “Seed-and-Boost” cell therapy for solid tumors combining CUE-100 with ImmunoScape TCRs |
| Upfront | $15M ($10M in Q4 2025, $5M in Nov 2026) |
| Equity | 40% stake in ImmunoScape |
| Royalties | High-single-digit on net sales |
| IND Target | 2027 |
? Boehringer Ingelheim Partnership (CUE-501)
| Upfront Received | $12M |
| Total Milestones | Up to $345M |
| Royalties | Tiered royalties on net sales |
4. Clinical Data Highlights
CUE-101 + Pembrolizumab (1L HPV16+ HNSCC)
| Metric | Result | Context |
|---|---|---|
| Overall Response Rate (ORR) | 50% | Includes new complete responses |
| 12-Month Overall Survival | 88% | Strong durability signal |
| Median Overall Survival | 32.7 months | Compares favorably to historical data |
| Safety Profile | No significant IL-2 toxicities | Key differentiator vs. high-dose IL-2 |
Clinical Significance: The mature survival data positions CUE-101 as an attractive partnering asset. The company is actively seeking a partner to fund Phase 2/3 development while focusing internal resources on CUE-401.
5. Financial Analysis (SEC-Verified)
5.1 Income Statement (Q3 2025)
| Item ($M) | Q3 2025 | Q3 2024 | Change |
|---|---|---|---|
| Collaboration Revenue | $2.1 | $3.3 | -36% |
| R&D Expenses | $4.8 | $9.4 | -49% |
| G&A Expenses | $4.9 | $2.9 | +69% |
| Net Loss | ($7.45) | ($8.66) | -14% |
| EPS (Diluted) | ($0.07) | ($0.17) | Improved |
5.2 Balance Sheet (September 30, 2025)
| Item | Sep 30, 2025 | Dec 31, 2024 |
|---|---|---|
| Cash & Equivalents | $11.7M | $22.5M |
| Total Assets | $18.2M | $28.4M |
| Total Liabilities | $8.1M | $9.2M |
| Stockholders’ Equity | $10.1M | $19.2M |
⚠️ Going Concern Warning: The Q3 2025 10-Q includes a going concern statement indicating insufficient capital to continue operations beyond the next twelve months without additional financing. However, the $10M ImmunoScape payment (Q4 2025) extends runway into H1 2026.
5.3 Pro-Forma Cash Position (Post-Deals)
| Item | Amount | Timing |
|---|---|---|
| Cash (Sep 30, 2025) | $11.7M | Reported |
| ImmunoScape Upfront #1 | +$10.0M | Q4 2025 |
| ImmunoScape Upfront #2 | +$5.0M | Nov 2026 |
| Estimated Cash Runway | Into Q2-Q3 2026 (before additional financing) | |
6. Upcoming Catalysts
? Q4 2025 — ImmunoScape Cash-In
$10M upfront payment from ImmunoScape collaboration expected to close in Q4 2025. Extends cash runway and validates oncology platform value.
? Q4 2025 / Q1 2026 — Corporate Update
New corporate presentation filed November 24, 2025 with CUE-401 as primary focus. Potential investor day or KOL event to detail autoimmune strategy and first indication (atopic dermatitis).
? H1 2026 — CUE-101 Survival Data Updates
Additional mature survival cuts from Phase 1 CUE-101 + pembro trial expected at oncology conferences (ASCO, ESMO IO). Could trigger partnering discussions.
⭐ Mid-2026 — CUE-401 IND Filing (KEY CATALYST)
Primary de-risking event. IND submission for CUE-401 in atopic dermatitis would transform the company from “platform story” to “clinical autoimmune biotech.” FDA Pre-IND feedback was positive.
? 2026 — Potential CUE-101/102 Partnering
With maturing survival data and validated mechanism, the oncology assets become increasingly attractive for licensing/partnering with larger pharma.
7. Key Risks
7.1 Financial/Dilution Risk
- Going concern warning in latest 10-Q — insufficient capital without additional financing
- Cash of $11.7M + $10M ImmunoScape = ~$21.7M, but burn rate ~$7-8M/quarter implies runway only into mid-2026
- Dilution likely before or around CUE-401 IND filing
7.2 Pipeline/Clinical Risk
- CUE-401 is still preclinical — IND filing ~6 months away, first clinical data 12-18 months out
- Oncology programs (CUE-101/102) deprioritized — success depends on finding a partner
- Platform technology unproven in autoimmune diseases (only oncology data so far)
7.3 Strategic Risk
- Pivot risk: Company pivoted from oncology to autoimmune in mid-2024 — execution on new strategy unproven
- Leadership change: New CEO (Usman Azam) as of September 2025 — transition period
- No near-term binary catalysts: Unlike CAPR, there’s no Phase 3 readout imminent
8. Valuation Scenarios
? Bull Case (18-24 months)
$3 – $5
CUE-401 IND filed successfully, first patients dosed, oncology partnering deal announced ($50M+ upfront). Market re-rates as “autoimmune platform with clinical validation.”
? Base Case
$0.80 – $1.50
CUE-401 advances on schedule, no major partnering deal, dilutive financing in H1 2026. Stock gradually re-rates as IND approaches.
? Bear Case
$0.20 – $0.40
CUE-401 development delays, no partnering interest for oncology, heavily dilutive financing or reverse split. Going concern becomes more acute.
Positioning Note: CUE is NOT a short-term catalyst play. Position sizing should reflect the 12-18 month timeline to CUE-401 clinical data and the significant financing/dilution risk. Suitable only for investors with high risk tolerance and multi-quarter holding period.
9. Sources & SEC Links
SEC Filings
Press Releases (GlobeNewswire)
Company Resources
?? Versione Italiana
? Cue Biopharma (CUE)
Investment Research Report — Platform Play: Modulatori T-Cell Immuno-STAT
Aggiornamento: 26 Novembre 2025
⚠️ GOING CONCERN WARNING
? PIVOT STRATEGICO SU AUTOIMMUNI
NASDAQ: CUE | Prezzo: ~$0.61 | Market Cap: ~$47M | Range 52-Settimane: $0.45 – $5.12
1. Executive Summary
Cue Biopharma è una biotech clinica che sviluppa biologici Immuno-STAT — farmaci iniettabili che modulano selettivamente i T-cell disease-relevant senza immunosoppressione sistemica. La piattaforma ha applicazioni sia in oncologia che nelle malattie autoimmuni.
A luglio 2024, la società ha annunciato un pivot strategico per prioritizzare i programmi autoimmuni (CUE-401) cercando partner per gli asset oncologici (CUE-101, CUE-102). Questo rappresenta un cambio fondamentale da biotech cancer-focused a autoimmune-focused.
Profilo di Investimento:
- NON è un play su catalyst binario a breve termine come CAPR o tipici titoli con PDUFA
- Tesi di medio termine: IND filing CUE-401 (metà 2026) + potenziali deal di partnering oncologia
- Eventi cash a breve: Pagamento ImmunoScape $10M (Q4 2025)
- Alto rischio: Going concern warning, runway limitata, pipeline early-stage
2. Overview Pipeline
? CUE-101 (Oncologia — Lead Asset Clinico)
Phase 1 In Cerca di PartnerTarget: Tumori HPV16-driven (HNSCC, cervicale, anale, orofaringeo)
Status: Phase 1 mono e combo (+ pembrolizumab) in corso; dati di sopravvivenza maturi
Dati Chiave: 50% ORR in combo, 12-month OS 88%, median OS 32.7 mesi
⭐ CUE-401 (Autoimmuni — PROGRAMMA LEAD)
Preclinico / IND-EnablingTarget: “Master switch” Treg — attivazione selettiva Treg senza immunosoppressione sistemica
Indicazione: Dermatite atopica (prima indicazione); potenziale in multiple malattie autoimmuni
Timeline: IND filing atteso metà 2026
? CUE-501 (Partnership con Boehringer Ingelheim)
PartneredEconomics: $12M upfront + fino a $345M milestones + royalties
3. Deal Strategiche Recenti
? Collaborazione ImmunoScape (Novembre 2025)
| Focus | Cell therapy “Seed-and-Boost” per tumori solidi |
| Upfront | $15M ($10M in Q4 2025, $5M in Nov 2026) |
| Equity | 40% stake in ImmunoScape |
| Royalties | High-single-digit sulle vendite nette |
4. Analisi Finanziaria (SEC-Verificata)
4.1 Stato Patrimoniale (30 Settembre 2025)
| Voce | 30 Set 2025 | 31 Dic 2024 |
|---|---|---|
| Cash & Equivalents | $11.7M | $22.5M |
| Totale Attività | $18.2M | $28.4M |
| Totale Passività | $8.1M | $9.2M |
| Patrimonio Netto | $10.1M | $19.2M |
⚠️ Going Concern Warning: Il 10-Q Q3 2025 include un avvertimento sulla capacità di continuare le operazioni oltre i prossimi dodici mesi senza finanziamenti aggiuntivi. Tuttavia, il pagamento ImmunoScape da $10M (Q4 2025) estende la runway fino a H1 2026.
5. Catalyst Prossimi
? Q4 2025 — Cash-In ImmunoScape
Pagamento upfront $10M dalla collaborazione ImmunoScape atteso in Q4 2025. Estende la runway e valida il valore della piattaforma oncologia.
? H1 2026 — Aggiornamento Dati Sopravvivenza CUE-101
Ulteriori cut di sopravvivenza dal trial Phase 1 CUE-101 + pembro attesi a conferenze oncologia (ASCO, ESMO IO). Potrebbe triggerare discussioni di partnering.
⭐ Metà 2026 — IND Filing CUE-401 (CATALYST CHIAVE)
Evento primario di de-risking. La submission IND per CUE-401 in dermatite atopica trasformerebbe la società da “platform story” a “biotech autoimmune clinica.”
6. Rischi Principali
- Going concern warning nell’ultimo 10-Q — capitale insufficiente senza finanziamenti aggiuntivi
- Cash di $11.7M + $10M ImmunoScape = ~$21.7M, ma burn rate ~$7-8M/trimestre implica runway solo fino a metà 2026
- Diluizione probabile prima o intorno al filing IND CUE-401
- CUE-401 è ancora preclinico — primi dati clinici a 12-18 mesi
- Programmi oncologia (CUE-101/102) deprioritizzati — successo dipende dal trovare un partner
7. Scenari Valutativi
? Bull Case (18-24 mesi)
$3 – $5
IND CUE-401 filed con successo, primi pazienti dosati, deal di partnering oncologia annunciato ($50M+ upfront). Il mercato re-rata come “piattaforma autoimmune con validazione clinica.”
? Base Case
$0.80 – $1.50
CUE-401 avanza nei tempi, nessun deal di partnering importante, finanziamento diluitivo in H1 2026. Il titolo gradualmente si re-rata con l’avvicinarsi dell’IND.
? Bear Case
$0.20 – $0.40
Ritardi nello sviluppo CUE-401, nessun interesse di partnering per oncologia, finanziamento pesantemente diluitivo o reverse split. Going concern diventa più acuto.
Nota di Posizionamento: CUE NON è un play su catalyst a breve termine. Il sizing della posizione dovrebbe riflettere la timeline di 12-18 mesi ai dati clinici CUE-401 e il significativo rischio di finanziamento/diluizione. Adatto solo a investitori con alta tolleranza al rischio e orizzonte di holding multi-trimestrale.